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Patients with type 1 diabetes (T1D) often experience gastrointestinal enteropathy (DE) of unclear etiology.
Now in Cell Stem Cell, D’Addio et al. (2015) utilize organoid culture models to study the roles of stem cells
in DE and show that circulating IGF/IGFBP3 controls colonic stem cell function during homeostasis and in
T1D patients.The mechanisms underlying how tissues
adapt to aberrant physiologic states are
unclear. Key protagonists in this question
are adult stem cells, which drive tissue
remodeling and couple organismal meta-
bolic demands to tissue maintenance.
Such coordination at the stem cell level
relies on an integrated cellular response
to local niche factors and systemic phys-
iologic hormones and growth factors (Mi-
haylova et al., 2014; Yilmaz et al., 2012). It
is likely that imbalances of these cues in
certain metabolic diseases, obesity, and
aging contribute to tissue-specific pathol-
ogies. In this issue ofCell StemCell, D’Ad-
dio et al. (2015) show that this is indeed
the case in type 1 diabetes (T1D) patients
with gastrointestinal (GI) complications.
Organismal metabolic status and cir-
culating factors are severely perturbed
in diabetic patients. T1D, which occurs
from autoimmune-mediated beta-cell de-
pletion, is caused by insulin deficiency,
and leads to weight loss. Type 2 diabetes
(T2D), on the other hand, often arises as a
consequence of obesity-driven metabolic
syndrome and is characterized by insulin
resistance. Both T1D and T2D are associ-
ated with hyperglycemia and result in
multi-organ degenerative complications
involving the nervous system (diabetic
neuropathy), the eyes (diabetic retinop-
athy), the kidneys (diabetic nephropathy),
and the GI tract (intestinal enteropathy).
It has been proposed that hyperglycemia-
mediated increase of hepatic IGFBP3 (in-
sulin-like growth factor binding protein 3)
secretion disrupts tissue regeneration dur-
ing the late stages of diabetes (D’Addio
et al., 2015). IGFBP3 is a multifunctional
protein predominantly produced by theliver. When it binds to IGF-1, it suppresses
the pro-growth effects of IGF-1 and in-
duces apoptosis. IGFBP3 can also act
independently of IGF-1 via interaction
with its own receptor, TMEM219, to induce
caspase-8-dependent apoptosis (Baxter,
2013). Whether IGFBP3 mediates some
of the untoward effects of diabetes in tis-
sue maintenance and stem cell function,
and, if so, whether it does so by seques-
tering IGF-1 or through interaction with its
receptor, is unknown. Until very recently,
this translationalquestionhasbeendifficult
to address, in part due to the lack of robust
ex vivo models that enable interrogation
of physiologic cues on tissue structure,
composition, and stem cell function.
Recent breakthroughs in mouse and
human intestinal cultures have estab-
lished conditions that allow intestinal
crypts to form self-renewing organoid
bodies (or ‘‘mini-intestines’’) (Lancaster
and Knoblich, 2014). These organoids
grow and recapitulate many of the histo-
logic features observed in the intestine
and thus represent an ideal platform to
study how perturbations in the systemic
and local milieu affect intestinal stem
cell function. Organoid formation and
growth are often used as proxies for
intestinal stem cell activity as only stem
cells self-renew and differentiate into
the various intestinal cell types that
comprise organoids. D’Addio et al. uti-
lized this technology to explore how
long-term T1D influences human colon
stem cell (CoSC) function and whether
the IGF-1/IGFBP3 dyad represents a
possible therapeutic intervention in T1D-
mediated diabetic enteropathy (DE)—a
clinical syndrome associated with diar-Cell Stem Cell 1rhea, intestinal motility issues, and intesti-
nal mucosal abnormalities (D’Addio et al.,
2015).
Interestingly, the authors demonstrate
that CoSCs from patients with T1D-end
stage renal disease (T1D-ESRD; i.e., pa-
tients with chronic disease) are reduced
in numbers and have impaired function
in the intestinal organoid assay. These
changes in CoSCs correlate with hyper-
glycemia, reduced free serum IGF-1, and
increased levels of circulating IGFBP3
shown by serum proteomic analysis (Fig-
ures 1A and 1B). Notably, CoSC defects
can be mimicked in the organoid assay
simply by exogenous exposure to T1D-
ESRD patients’ serum or IGFBP3 protein
directly; these inhibitory effects can be
reversed by treatments with either cas-
pase 8 or caspase 9 inhibitors. Although
additional IGF-1 is sufficient to rescue
some defects of T1D-ESRD-derived orga-
noids, it fails to completely rescue the
inhibitory effects that T1D-ESRD serum
or exogenous IGFBP3 have on organoid
growth. This suggests that IGFBP3 may
activate TMEM219 on CoSCs to mediate
effects on organoid formation and mainte-
nance independent of IGF-1.
An important question is whether
changes in intestinal morphology and
CoSC function are reversible in patients
with T1D-ESRD. Remarkably, restoration
of euglycemia in T1D-ESRD subjects
by simultaneous pancreas-kidney (SPK)
transplantation normalizes IGF-1 and
IGFBP3 levels, improves intestinal
mucosal abnormalities, and augments the
organoid-forming capacity of CoSCs
(Figure 1C, SPK). To interrogate whether
inhibiting IGFBP3 signaling is sufficient to7, October 1, 2015 ª2015 Elsevier Inc. 379
Figure 1. Peripheral IGF-1/IGFBP3 Regulates the Function of Human CoSCs
(A) In normal physiology, low basal levels of IGFBP3 bind to free IGF-1 and to the TMEM219 receptor, which (1) allows excess IGF-1 to bind to IGF-1R to promote
CoSCs proliferation and (2) minimizes IGFBP3/TMEM219-mediated apoptosis.
(B) In type 1 diabetes (T1D), hyperglycemia increases circulating IGFBP3 that competitively binds to IGF-1, which (1) dampens pro-growth IGF-1/IGF-1R signaling
and (2) augments IGFBP3/TMEM219-mediated apoptosis.
(C) Restoration of euglycemia by simultaneous pancreas-kidney (SPK) transplantation normalizes the levels of IGFBP3, while exogenous ecto-TMEM219 se-
questers IGFBP3 and prevents it from binding to TMEM219. Both of these interventions shift IGFBP3/TMEM219-mediated apoptosis toward IGF-1/IGF-1R-
activated CoSC proliferation in T1D.
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phenotype, the authors engineered a re-
combinant protein based on the 161-
amino-acid TMEM219 extracellular do-
main (ecto-TMEM219) that binds excess
systemic IGFBP3 to prevent it from
activating TMEM219 onCoSCs. Strikingly,
in organoid cultures exposed to T1D-
ESRD serum and in an in vivo preclinical
T1Dmousemodel, ecto-TMEM219admin-
istration reverses the inhibitory effects of
T1D serum on organoid growth and re-
stores intestinal morphology in vivo
(Figure 1C, ecto-TMEM219). These find-
ings indicate that elevated IGFBP3
signaling through the TMEM219 receptor
potentially contributes to the detrimental
effectsonCoSC functionanddegenerative
intestinal mucosa in T1D. Another implica-
tion of these findings is that IGFBP3/
TMEM219 signaling may represent a new
treatment axis for DE that is separate
from the insulin/glucose axis, which is
what most contemporary treatment inter-
ventions target for treating complications
of diabetes.
This study provides important insights
into how systemic factors couple intestinal
homeostasis to organismal physiology
and how dysregulation of such factors,
like IGFBP3, in T1D impair the function
of human CoSCs and contribute to DE.380 Cell Stem Cell 17, October 1, 2015 ª201It also provides a rationale for targeting
elevated circulating levels of IGFBP3 for
treatment of T1D-induced DE. However,
open questions remain about the binding
dynamics and physiological actions of
ecto-TMEM219 in human patients. In
particular, IGF-1R and TMEM219 are
broadly expressed throughout the entire
GI tract and in many other organs such
as the kidneys. Therefore, further work
to elucidate the effects of disrupting
IGFBP3/TMEM219 signaling on other tis-
sues in the context of normal physiology
and in T1D is needed. Such studies, in
fact, may also leverage the use of
pancreas or kidney organoid technology
(Lancaster andKnoblich, 2014). In addition
to T1D-mediated hyperglycemia, obesity-
driven T2D diabetes also is associated
with GI complications (Shakil et al., 2008).
Although both T1D and T2D are charac-
terized by hyperglycemic states, T2D pa-
tients exhibit an array of other metabolic
abnormalities such as insulin resistance
in many tissues, dysfunction of growth
hormone (GH)-IGF-1 signaling, and dysli-
pidemia. It will be interesting to apply the
current experimental paradigm to study
how the systemic milieu in T2D patients
influences intestinal stem cell function
and how obesity and T2D contribute to
the increased incidence of gastrointestinal5 Elsevier Inc.cancers. While TMEM219 inhibition could
potentially be therapeutically relevant for
T2D patients, such a strategy will need
to be compared to the standard first
line therapies such as Metformin, which
has been shown to decrease unbound
IGF-1 levels by increasing amounts of its
binding protein IGFBP1. In conclusion,
this study uncovers novel mechanisms
for how perturbed IGFBP3/TMEM219
signaling in T1D contributes to intestinal
enteropathy and paves the way for a po-
tential new therapeutic approach.REFERENCES
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